Canaccord Genuity maintained BioMarin Pharmaceutical (NASDAQ: BMRN ) with a Buy rating and raised the price target from $56.00 to $71.00. Canaccord Genuity commented, "Given that we view 2013 as a key value inflection point for BMRN's pipeline and did not previously include 5 of the 6 drugs (excludes Vimizim)